Market cap
$4 Mln
Market cap
$4 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.8 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.2
Debt to Equity
0.4
Book Value
$16.8
EPS
$-8.9
Face value
--
Shares outstanding
2,877,926
CFO
$-29.74 Mln
EBITDA
$-30.24 Mln
Net Profit
$-35.06 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tivic Health Systems Inc (TIVC)
| -27.9 | 4.5 | 1.5 | -76.6 | -83.3 | -- | -- |
|
BSE Sensex*
| -9.0 | 5.0 | -8.1 | -4.3 | 7.6 | 9.8 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Tivic Health Systems Inc (TIVC)
| -75.4 | -80.5 | -97.2 | -83.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tivic Health Systems Inc (TIVC)
|
1.0 | 4.0 | 0.4 | -8.9 | -1,404.5 | -91.8 | -- | 0.2 |
| 8.0 | 5,434.7 | 6,552.2 | -551.4 | -6.1 | -9.9 | -- | 1.0 | |
| 299.5 | 8,082.3 | 2,589.9 | 168.8 | 21.4 | 2.5 | 49.7 | 1.2 | |
| 38.0 | 5,600.3 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.3 | |
| 134.7 | 8,206.7 | 551.4 | -189.3 | -15.6 | -26.3 | -- | 12.2 | |
| 86.8 | 5,566.3 | 1,541.6 | 233.6 | 21.6 | 21.4 | 25.1 | 5.1 | |
| 178.2 | 9,345.7 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.5 | 13.0 | |
| 324.6 | 12,795.7 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72 | 9.0 | |
| 124.6 | 6,610.0 | 738.3 | 48.9 | 11.4 | 2.4 | 136.3 | 3.1 | |
| 31.5 | 13,298.7 | 6,178.4 | 626.5 | 13.0 | 11.9 | 21.8 | 2.5 |
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat... Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas. Address: 47685 Lakeview Blvd., Fremont, CA, United States, 94538 Read more
Co-Founder, CEO & Director
Ms. Jennifer Ernst
Co-Founder, CEO & Director
Ms. Jennifer Ernst
Headquarters
Fremont, CA
Website
The share price of Tivic Health Systems Inc (TIVC) is $1.05 (NASDAQ) as of 04-May-2026 09:30 EDT. Tivic Health Systems Inc (TIVC) has given a return of -83.3% in the last 3 years.
Since, TTM earnings of Tivic Health Systems Inc (TIVC) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.16
|
0.09
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Tivic Health Systems Inc (TIVC) are Rs 5.60 and Rs 0.72 as of 05-May-2026.
Tivic Health Systems Inc (TIVC) has a market capitalisation of $ 4 Mln as on 01-May-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Tivic Health Systems Inc (TIVC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.